Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma

SUMMIT, N.J. — (BUSINESS WIRE) — Celgene Corporation (NASDAQ:CELG) today announced results from the OPTIMISMM study, a phase III, randomized, open-label, international clinical study of the …